potential for CYP450 inhibition or induction and the therapeutic index of the medications in question.
In a recent study comparing the effect of the antidepressant sertraline with placebo in schizophrenia patients with depression (3), serum levels of sertraline and antipsychotics were obtained to identify possible pharmacokinetic drug interactions. Here we report the results of serum monitoring in patients receiving antipsychotic monotherapy compared with antipsychotics combined with sertraline.
Methods
The study was approved by a research ethics committee, and the details of the study design have been published elsewhere (3) . Participants were aged 18 to 65 years, with DSM-IV major depression comorbid with schizophrenia (or schizoaffective disorder) in partial or full remission. In this double-blind trial, 48 participants (n = 44 with schizophrenia and n = 4 with schizoaffective disorder) were randomized following written informed consent to placebo for 6 weeks or sertraline 50 mg for 4 weeks, followed by sertraline 50 to 100 mg for 2 weeks if they showed no evidence of response. Participants were on a stable antipsychotic regimen.
Clinical outcomes were assessed weekly for 6 weeks with the CDSS (4), the Positive and Negative Syndrome Scale (5), the Extrapyramidal Symptom Rating Scale (6) , and the HDRS (7) . Serum samples were collected at Weeks 1, 5, and 6 for drug monitoring. The time and date of last dose taken and of blood sampling were recorded. Serum drug concentrations were measured with standard assays for both sertraline and antipsychotics.
A 20% change in antipsychotic serum levels was defined as meaningful on the basis of therapeutic drug monitoring studies with risperidone (8) and olanzapine (9) . Fisher's exact tests were performed with Stata, Version 8.0 (Stata Corporation, College Station, TX; 2003) to compare fluctuations in antipsychotic levels between groups.
Results
Twenty-one participants were randomized to sertraline and 27 to placebo. As previously reported (3), the demographics of the 2 groups were comparable ( Table 1) . Patients were taking a wide range of antipsychotics (Table 2) , and there was no change in positive psychotic symptoms in either group over 6 weeks of follow-up. There was a significant decrease in depressive symptoms in the sample overall as measured by the CDSS (P < 0.001) and the HDRS (P < 0.001). The placebo group went from a CDSS score of 13.3 to 8.8 and from an HDRS score of 20 to 15, while the sertraline-treated group went from a CDSS score of 14.8 to 8.6 and an HDRS score of 20 to 15, with no differences between the groups.
There was no clinical evidence of drug interactions, including no increase in extrapyramidal side effects in sertraline-treated patients. Both placebo-and sertraline-treated patients displayed minor fluctuations in antipsychotic levels over the 6-week period ( In the placebo group, 4 patients had altered drug levels explained by variation in the timing of blood sampling in relation to time of last dose, whereas in the sertraline-treated group, 6 patients had such variability. The range of drug levels in sertraline-treated patients was comparable to that of placebo-treated patients.
Discussion
Changes in antipsychotic serum levels following the addition of sertraline 50 mg to 100 mg daily to antipsychotic monotherapy were not clinically significant during the course of this study, suggesting combination treatment with sertraline is a safe option in schizophrenia patients with depression who are taking antipsychotics. Given that fluctuations in antipsychotic serum levels were observed in both groups, the variability likely occurred as a result of factors other than sertraline. Fixed factors, including P450 phenotype and sex (12) , contribute to metabolic variability between subjects; however, the focus here is on intrasubject variability of drug levels, commonly attributable to such factors as drug interactions, variable timing of dosing or sampling, dietary intake, smoking status, alcohol use, and compliance. The latter 4 variables were not assessed in this study, which limits the interpretation of the data. However, variable timing of dosing or sampling was found to explain the variation in blood levels seen in 10 study patients.
In keeping with our findings, sertraline has been shown to have no significant effect on antipsychotic drug levels when combined with CYP2D6-metabolized risperidone (13) or CYP1A2-metabolized olanzapine (14) and clozapine (15) . Modest but significant increases in haloperidol serum levels have been observed when coadministered with sertraline (16) . In our study, 2 of 3 patients taking sertraline in combination with haloperidol demonstrated a 20% or greater increase in haloperidol serum levels; however, there was no clinical evidence of associated adverse effects.
Despite variable serum levels of antipsychotics, patients were stable in regard to symptoms and side effects. Pharmacokinetic drug interactions do not appear to be a significant concern when using sertraline for the treatment of depression in people with schizophrenia.
Funding and Support The study was supported by a grant from the Medical Research Council of Canada. Résultats : Dans les deux groupes, celui traité au placebo et celui à la sertraline, la plupart des patients ont présenté des fluctuations mineures des taux sériques d'antipsychotique, sur 6 semaines. Il n'y avait pas de preuves cliniques d'interactions des médicaments dans le groupe traité à la sertraline.
Table 3 Fluctuation of antipsychotic serum levels in patients taking placebo or sertraline

Conclusions :
Aucun effet indésirable cliniquement significatif ne s'est produit, malgré les taux sériques d'antipsychotiques variables, avec ou sans sertraline. Les préoccupations au sujet des interactions pharmacocinétiques ne devraient pas empêcher l'utilisation de sertraline pour la dépression chez les personnes souffrant de schizophrénie.
